Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Feher

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Heart (British Cardiac Society)|March 18, 2003
Lipid lowering to delay the progression of coronary artery diseaseMichael D Feher
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|August 7, 2008
Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetesNeil Munro, Michael D Feher
The New England Journal of Medicine|January 30, 2004
GoutAlastair L Hepburn, Michael D Feher
Current Medical Research and Opinion|March 18, 2016
Hypoglycemia, diabetes therapies and driving categories in type 2 diabetesMichael D Feher, Haya Langerman, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 2, 2019
How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study ProtocolWilliam Hinton, Michael D Feher, Neil Munro, et al.
Diabetes Research and Clinical Practice|May 27, 2020
The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19Martin B Whyte, Prashanth Vas, Christian Heiss, et al.
Cardiovascular Diabetology|June 29, 2021
Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosisWilliam Hinton, Michael D Feher, Neil Munro, et al.
The Lancet. Diabetes & Endocrinology|May 28, 2018
Novel diabetes subgroupsMichael D Feher, Neil Munro, David Russell-Jones, et al.
BMJ Open Diabetes Research & Care|May 10, 2016
Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomesMichael D Feher, John Brazier, Nicolaas Schaper, et al.
Journal of Neurochemistry|April 12, 2002
Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidationAnthony S Wierzbicki, Matthew D Lloyd, Christopher J Schofield, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Heart (British Cardiac Society)|March 18, 2003
Lipid lowering to delay the progression of coronary artery diseaseMichael D Feher
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|August 7, 2008
Current, new, and emerging therapies for managing hyperglycaemia in type 2 diabetesNeil Munro, Michael D Feher
The New England Journal of Medicine|January 30, 2004
GoutAlastair L Hepburn, Michael D Feher
Current Medical Research and Opinion|March 18, 2016
Hypoglycemia, diabetes therapies and driving categories in type 2 diabetesMichael D Feher, Haya Langerman, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 2, 2019
How Generalizable Are Cardiovascular Outcome Trials of Sodium-Glucose Co-Transporter-2 Inhibitors? A National Database Study: Study ProtocolWilliam Hinton, Michael D Feher, Neil Munro, et al.
Diabetes Research and Clinical Practice|May 27, 2020
The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19Martin B Whyte, Prashanth Vas, Christian Heiss, et al.
Cardiovascular Diabetology|June 29, 2021
Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosisWilliam Hinton, Michael D Feher, Neil Munro, et al.
The Lancet. Diabetes & Endocrinology|May 28, 2018
Novel diabetes subgroupsMichael D Feher, Neil Munro, David Russell-Jones, et al.
BMJ Open Diabetes Research & Care|May 10, 2016
Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomesMichael D Feher, John Brazier, Nicolaas Schaper, et al.
Journal of Neurochemistry|April 12, 2002
Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidationAnthony S Wierzbicki, Matthew D Lloyd, Christopher J Schofield, et al.
Pageof 3